3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NIH
4
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
69
Neoplasms
20
Neoplasm Metastasis
12
Brain Neoplasms
4
Stomach Neoplasms
2
Recurrence
2
Osteitis Deformans
2
Inflammatory Breast Neoplasms
2
Head and Neck Neoplasms
2
HER2 Positive Metastatic Breast Cancer
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
HER2-positive Advanced Breast Cancer
1
HER2+ Metastatic Breast Cancer (MBC)
1
HER-2 Gene Amplification
1
Glioma
1
Glioblastoma
1
Diarrhea
1
Carcinoma
1
Breast Diseases
1
Advanced Solid Tumors
1
Adenocarcinoma
1
Interventions
Temozolomide
94
Radiotherapy
40
Bevacizumab
40
Lomustine
21
Radiation
18
Surgical Procedures, Operative
10
Carboplatin
9
pembrolizumab
8
Nivolumab
8
Carmustine
8
Irinotecan
7
IL13-PE38
6
Granulocyte-Macrophage Colony-Stimulating Factor
6
Flucytosine
6
Cyclophosphamide
6
ABT-414
6
vocimagene amiretrorepvec
5
depatuxizumab mafodotin
5
Valacyclovir
5
Drug Therapy
5
veledimex
4
sargramostim
4
enzastaurin
4
NVP-BKM120
4
Gemcitabine
4
Dianhydrogalactitol
4
Chlorotoxin
4
Aminolevulinic Acid
4
verubulin
3
selinexor
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Glioblastoma
×
Lapatinib
×
Clear all
NCT00350727
2013-04-19
VEG102857
GlaxoSmithKline
Phase 2
Completed
75 enrolled
45 charts